Legend

A preliminary short form prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in British Columbia, Alberta, Manitoba, Ontario and Québec. A copy of the preliminary short form prospectus, and any amendment, is required to be delivered with this document. The preliminary short form prospectus is still subject to completion. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final short form prospectus has been issued. This document does not provide full disclosure of all material facts relating to the securities offered. Investors should read the preliminary short form prospectus, the final short form prospectus and any amendment for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.

A Form S-1 registration statement dated December 19, 2019 (the “Registration Statement”) was filed with the United States Securities and Exchange Commission (“SEC”) which contains important information relating to the securities described in this investor presentation. Before you invest, you should read the prospectus in that Registration Statement and other documents the issuer has filed and will file with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting the Electronic Data Gathering, Analysis and Retrieval system on the SEC website at www.sec.gov.

2

Notice to Reader

Included in this investor presentation is certain forward looking information, as such term is defined under applicable securities laws. This information relates to future events or future performance and reflects management’s expectations and assumptions regarding the growth, results of operations, performance and business prospects and opportunities of IntelGenx Technologies Corp. (“IntelGenx”). Such forward-looking information reflects management’s current beliefs and are based on information currently available to management of IntelGenx and a number of assumptions that management believed were reasonable on the day such forward-looking information was presented. Refer, in particular, to the relevant sections of the preliminary short form prospectus dated December 18, 2019 (the “Prospectus”) and the documents incorporated by reference therein as well as the Registration Statement and the documents incorporated by reference therein, for a discussion of certain assumptions management has made in presenting forward looking information. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other similar expressions concerning matters that are not historical facts. In particular, information regarding IntelGenx’s future operating results and economic performance is forward-looking information. A number of factors could cause actual events or results to differ materially from the events and results discussed in the forward-looking information. Refer to the “Risk Factors” section in the Prospectus.

Forward-looking statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and other uncertain events. Forward-looking statements, by their nature, are based on assumptions, including those described below, and involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to differ materially from those expressed in the forward-looking statements. Any forecasts or forward-looking predictions or statements cannot be relied upon due to, among other things, changing external events and general uncertainties of the business. Results indicated in forward-looking statements may differ materially from actual results for a number of reasons, including without limitation, risks associated with the ability to obtain sufficient and suitable financing to support operations, R&D clinical trials and commercialization of products; the ability to execute partnerships and corporate alliances; uncertainties relating to the regulatory approval process; the ability to develop drug delivery technologies and manufacturing processes that result in competitive advantage and commercial viability; the impact of competitive products and pricing and the ability to successfully compete in the targeted markets; the successful and timely completion of pre-clinical and clinical studies; the ability to attract and retain key personnel and key collaborators; the ability to adequately protect proprietary information and technology from competitors; and the ability to ensure that IntelGenx does not infringe upon the rights of third parties. Material factors or assumptions that were applied in drawing a conclusion or making an estimate set out in the forward-looking information include the factors identified throughout this investor presentation and in particular, the “Risk Factors” section of the Prospectus. The forward-looking statements contained in this investor presentation represent IntelGenx’s expectations as of the date of this investor presentation, and are subject to change after such date. IntelGenx disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations. IntelGenx undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which such statements were made or to reflect the occurrence of unanticipated events, except as may be required by applicable securities laws.

This investor presentation is a summary of the principal features of the Offering and should be read together with the more detailed information and financial data and statements contained in the Prospectus. Terms undefined herein have the meanings ascribed to them in the Prospectus.

This investor presentation does not constitute an offer to sell or a solicitation of an offer to buy any of the securities nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

3

Growth Strategy
Three Primary Pillars for Future Value Creation

7

Proof of Concept Phase IIa Clinical Study Currently Underway

“A randomized Phase IIa, multi-center, double-blind, placebo-controlled study to assess the safety, feasibility, tolerability, and efficacy of a new buccal film of Montelukast in patients with mild to moderate Alzheimer’s Disease”

11

Terms of Offering

18